Articles related to Gastroenterology

Medtronic is collaborating with Nvidia on developing means to allow AI to run on its devices. The solution will use Nvidia chips on Medtronic devices and an AI layer that would allow doctors to create their own algorithms to run on the machines. The first will be implemented on the GI Genius endoscopy module. Medtronic hopes the strategy will mean that millions of users around the globe will be contributing to making their devices more capable and flexible for the diversity of real-world clinic challenges.

Five-hundred thirty-five (535) digitalized biopsies were graded against three standard indexes. A neural network was trained to distinguish remission from activity. The model predicted endoscopic-verified remission or activity with approximately 80% accuracy.

Long-term outcomes of lifestyle interventions to promote weight maintenance — the current first-line management for patients with NAFLD — are often unsatisfactory. DTx can overcome the drawbacks of traditional lifestyle treatments through telecare medical services. At the same time, implementing DTx introduces a different level of self-management motivation for patients, greatly improving the treatment adherence and therapeutic effect among NAFLD patients.

A 56-year-old man with no significant medical history, who previously refused colonoscopy for colorectal cancer screening, visited his primary care physician. Despite the physician’s recommendations, the patient declined colonoscopy and instead preferred a less invasive screening test. The patient had no symptoms of colorectal issues but had a family history of his father dying from colorectal cancer at age 80. The patient’s hemoglobin level was within the normal range at 13.7 g/dL.

A young woman with ulcerative colitis in remission on 5-ASA and azathioprine is seen for annual follow up. Immunizations are current and her depression and anxiety screens are negative. Review her current status and select the most important health maintenance screen.

Data on patients with mismatch repair deficiency (MMRD) CRC, the majority of whom could not undergo surgery due to various health conditions unrelated to cancer, were presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). Instead of radiation therapy or chemotherapy, the patients received immunotherapy with checkpoint inhibitors. It should be noted that the patients were treated outside of clinical trials. The overall response rate in this patient group was 74%, with 57% of those who responded experiencing complete tumor regression. Some of the patients have been in complete remission for a year or more after their diagnoses. The data indicate that immunotherapy is an effective treatment for patients who are unable to undergo surgery for a variety of reasons, including advanced age or a variety of health issues.